Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AAR

Biogen Idec building

EMA starts review of Biogen Idec’s haemophilia A therapy

Elocta already on the market in the US, Canada and Australia

- PMLiVE

Orphan drugs lead CHMP recommendations

Clinuvel's Scenesse is first drug set for European approval to treat rare intolerance to sunlight

- PMLiVE

Amgen should split up, says investor

Hedge fund manager Daniel Loeb criticises big biotech firm's 'bloated cost structure'

- PMLiVE

Amgen should split up, says investor

Hedge fund manager Daniel Loeb criticises big biotech firm's 'bloated cost structure'

- PMLiVE

Amgen appoints R Sanders Williams to board of directors

He is president of Gladstone Institutes

- PMLiVE

EMA offers orphan drug benefits for Ebola research

Incentives to encourage development of new treatments for the virus

- PMLiVE

Amgen files lawsuit to block PCSK9 rivals

Firm suing Sanofi and Regeneron for patent infringement

EMA expands adverse event reporting website

Opens it up to all nationally-authorised medicines

- PMLiVE

EMA safety panel rules no change needed for Ariad’s Iclusig

Positive news comes after blood clot concerns

- PMLiVE

Amgen leukaemia drug gets FDA priority review

Adds to breakthrough status for blinatumomab

- PMLiVE

Amgen biosimilar matches AbbVie’s Humira in psoriasis trial

ABP 501 set to compete with world’s biggest-selling drug

- PMLiVE

EMA draws fire on new clinical reports policy

Has recently come under pressure from transparency groups

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links